You are here
Clinical Trial Capacity Working Group
On this page
Develop an inventory of clinical trial capacity, including networks from NIH Institutes and Centers and contract research organizations (CROs), that will serve as potential settings in which to implement effective COVID-19 clinical trials. The working group completed its charge as of July 31, 2020.
Check mark indicates completion.
✓ Clinical Trial Capacity Survey and Inventory
The working group developed and launched a series of three clinical trial capacity surveys that included questions designed to identify the capabilities of more than 60 networks, over 700 clinical trial sites, and over 30 CROs and site management organizations (SMOs). The results of these surveys were combined with geographic mapping, COVID-19 disease incidence data, and visualization capabilities into a unique “geotracking tool” that has enabled the ACTIV therapeutics and vaccines clinical trial teams to choose the most effective networks and sites to support ACTIV master protocols and associated trials.
✓ Clinical Trial Innovations and Resources
The working group created a reference guide for novel clinical trial innovations along with a resource map of available solutions to help enable the safe and efficient conduct of ACTIV clinical trials under the unique conditions imposed by the COVID-19 pandemic. Working group members worked with healthcare professionals conducting clinical trials sponsored by ACTIV and its partners to identify useful solutions for ACTIV clinical trials.
This page last reviewed on September 11, 2020